20 terminated. 20 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Terminated 20 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Mycoses: new trials by email Literature Review of Mycoses trials Research Report on Mycoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections pathogen-specific CTLs - Pathogen Infection, EBV Infection | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-08-24 |
| Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA Itraconazole Powder, Placebo - ABPA | Phase 2 | Terminated | Pulmatrix Inc. | 8 | 2023-02-01 | 2024-04-02 |
| Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds fosmanogepix - Invasive Fungal Infections | Phase 2 | Terminated | Basilea Pharmaceutica | 21 | 2020-01-04 | 2025-09-16 |
| The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. PC945, Standard of Care - Aspergillosis, Lung Transplant Infection | Phase 2 | Terminated | Pulmocide Ltd | 2 | 2019-09-17 | 2021-07-16 |
| Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis PUR1900, Placebo - Allergic Bronchopulmonary Aspergillosis | Phase 2 | Terminated | Pulmatrix Inc. | 7 | 2019-07-31 | 2021-08-27 |
| The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis PC945 - Aspergillosis, Cystic Fibrosis | Phase 2 | Terminated | Pulmocide Ltd | 4 | 2019-04-03 | 2021-07-16 |
| Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis SCY-078, Voriconazole, Oral Placebo Tablets - Invasive Pulmonary Aspergillosis | Phase 2 | Terminated | Scynexis, Inc. | 22 | 2019-01-22 | 2024-08-09 |
| VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B - Invasive Aspergillosis, Invasive Pulmonary Aspergillosis | Phase 2 | Terminated | Vical | 4 | 2018-02-20 | 2019-02-27 |
| NLA101 in Adults Receiving High Dose Chemotherapy for AML NLA101, Standard of Care (SOC) chemotherapy - Leukemia, Myeloid, Acute | Phase 2 | Terminated | Nohla Therapeutics, Inc. | 146 | 2018-01-24 | 2021-03-30 |
| Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis S2G6T-1, S2G6T-2, S2G6T-3 - Tinea Pedis | Phase 2 | Terminated | Sol-Gel Technologies, Ltd. | 283 | 2016-09-01 | 2020-11-18 |
| Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064) Caspofungin, Amphotericin B Deoxycholate - Candidiasis, Invasive | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 51 | 2014-01-15 | 2019-11-25 |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients Placebo, QBW251 - Cystic Fibrosis | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 153 | 2012-07-31 | 2020-12-30 |
| Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067) Caspofungin acetate, Placebo - Invasive Candidiasis | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 15 | 2010-12-01 | 2017-03-24 |
| Anidulafungin in Patients With Hematologic Malignancies Anidulafungin - Hematologic Malignancies | Phase 2 | Terminated | Elisabethinen Hospital | 10 | 2009-10-01 | 2012-03-02 |
| Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment nikkomycin Z, Placebo - Coccidioidomycosis | Phase 1 / Phase 2 | Terminated | University of Arizona | 6 | 2007-09-01 | 2025-04-16 |
| Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Mycograb, placebo - Cryptococcal Meningitis | Phase 2 | Terminated | Novartis Pharmaceuticals | 3 | 2007-03-01 | 2008-12-12 |
| Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Efungumab (Mycograb), placebo, Amphotericin B - Cryptococcal Meningitis | Phase 2 | Terminated | Novartis Pharmaceuticals | 38 | 2006-08-01 | 2009-02-19 |
| Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV Isoniazid (INH), Trimethoprim/Sulfamethoxazole (TMP/SMX), Isoniazid Placebo (PL) - HIV Infection, Tuberculosis | Phase 2 / Phase 3 | Terminated | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 1354 | 2004-02-01 | 2019-02-05 |
| Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis Micafungin, Liposomal Amphotericin B - Aspergillosis | Phase 2 | Terminated | Astellas Pharma Inc | 2 | 2002-12-01 | 2014-08-20 |
| Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole L-743,872 - Candidiasis, Oral, HIV Infections | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 70 | 2005-06-24 |
Aspergillosis (6) · Aspergillosis, Allergic Bronchopulmonary (3) · Candidiasis, Invasive (3) · Cystic Fibrosis (2) · HIV Infections (2) · Invasive Fungal Infections (2) · Invasive Pulmonary Aspergillosis (2) · Meningitis, Cryptococcal (2) · Tuberculosis (2) · AIDS-Related Opportunistic Infections (1) · Adenoviridae Infections (1) · Asthma (1) · Bacterial Infections (1) · COVID-19 (1)
Bacterial Infections and Mycoses (20) · Infections (20) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Lung Diseases, Fungal (7) · Immune System Diseases (5) · Pulmonary Aspergillosis (5) · Respiratory Tract Infections (5) · Invasive Fungal Infections (4) · Virus Diseases (4) · Aspergillosis (3) · Candidiasis (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3)
Caspofungin (3) · Standard of Care (2) · efungumab (2) · liposomal amphotericin B (2) · Amphotericin B (1) · Anidulafungin (1) · Drug Therapy (1) · Flucytosine (1) · Isoniazid (1) · Micafungin (1) · Saline Solution (1) · Sulfamethoxazole (1) · Trimethoprim (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · Voriconazole (1)
Merck Sharp & Dohme LLC (3) · Novartis Pharmaceuticals (3) · Pulmatrix Inc. (2) · Pulmocide Ltd (2) · Astellas Pharma Inc (1) · Basilea Pharmaceutica (1) · Elisabethinen Hospital (1) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (1) · Nohla Therapeutics, Inc. (1) · Scynexis, Inc. (1) · Shenzhen Geno-Immune Medical Institute (1) · Sol-Gel Technologies, Ltd. (1) · University of Arizona (1) · Vical (1)
United States (12) · United Kingdom (5) · Belgium (4) · Germany (4) · Australia (3) · France (3) · South Africa (3) · Canada (2) · South Korea (2) · Austria (1) · Botswana (1) · China (1) · India (1) · Ireland (1) · Israel (1)
Charles D. Mitchell, MD (1) · Chris Cabell, MD (1) · David Angulo, MD (1) · David Denning, FRCP, FRC Path, FIDSA, FMedSci (1) · David E Nix, Pharm D (1) · George McSherry, MD (1) · Kathleen O Ashenfelter, MS (1) · Lung-Ji Chang, PhD (1) · Mammen P Mammen, MD, FIDSA (1) · Marc Engelhardt (1) · Martin S Tallman, MD (1) · Michael Girschikofsky, MD (1)
PMID 18230259, PMID 20607114, PMID 21732834, PMID 26872154, PMID 31586424, PMID 33293212, PMID 40203286
2018 (3), 2009 (1), 2017 (1), 2019 (1), U01AI068632 (1)